Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03820141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Study acronym: DTP
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results first posted: Apr 20, 2026v15
  2. Start date: Mar 3, 2020 to Jun 30, 2020v14
  3. Primary endpoint revised Enrollment target: estimated 39 to confirmed 51 · Completion date: Dec 2025 to Dec 2028 · Secondary endpoints revised (4)v13 Show 3 more changesShow less
    • Enrollment target: estimated 39 to confirmed 51
    • Completion date: Dec 2025 to Dec 2028
    • Secondary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Sep 2024 to Oct 30, 2024 · Completion date: Feb 2025 to Dec 2025 · Site details revisedv12 Show 3 more changesShow less
    • Primary completion date changed from estimate of Sep 2024 to Oct 30, 2024
    • Completion date: Feb 2025 to Dec 2025
    • Site details revised
  5. Eligibility criteria expanded, about 60 wordsv11 See this version in full on ClinicalTrials.gov ↗
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Mar 2023 to Sep 2024 Completion date: Aug 2023 to Feb 2025 · Eligibility criteria shortened, about 103 wordsv10 Show 2 more changesShow less
    • Completion date: Aug 2023 to Feb 2025
    • Eligibility criteria shortened, about 103 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv9
  3. Lead sponsor: Jenny C. Chang, MD to The Methodist Hospital Research Institutev8
  4. Re-verified, no change to tracked fieldsv7
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2019 to Mar 3, 2020 · Site details revisedv6 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2019 to Mar 3, 2020
    • Site details revised
  6. Start date: Aug 2019 to Dec 2019v5
  7. Start date: Jun 2019 to Aug 2019v4
  8. Re-verified, no change to tracked fieldsv3
  9. Start date: Apr 2019 to Jun 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
Trial Details
NCT Number NCT03820141
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: AstraZeneca
Conditions Breast Cancer
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov